The team led by PD Dr. Markus Chmielewski at the Center for Molecular Medicine Cologne (ZMMK) presents a new strategy for making CAR T-cell-based immunotherapy more effective and safer. The study was published in the journal Cell Reports Medicine under "An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL."
Original publication:
https://www.sciencedirect.com/science/article/pii/S2666379124000442
The two-week ceasefire agreed upon on Tuesday between the USA, Israel, and Iran marks the preliminary end of an escalation that has gripped the Middle East since February 2026.
A winter storm with up to 15 centimeters of new snow has plunged Germany into traffic chaos. Highways and country roads are blocked in many places, accidents are increasing, and the…
Dementia is a progressive brain disease that leads to a decline in cognitive abilities. It affects memory, thinking, orientation, and the…
